These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 14522520

  • 1. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients.
    Rolston KV, Frisbee-Hume S, LeBlanc B, Streeter H, Ho DH.
    Diagn Microbiol Infect Dis; 2003 Oct; 47(2):441-9. PubMed ID: 14522520
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
    Rolston KV, Frisbee-Hume S, LeBlanc BM, Streeter H, Ho DH.
    Diagn Microbiol Infect Dis; 2002 Oct; 44(2):187-94. PubMed ID: 12458127
    [Abstract] [Full Text] [Related]

  • 3. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
    Aktaş Z, Gönüllü N, Salcioğlu M, Bal C, Anğ O.
    Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH, Wang JT, Chen YC, Chang SC, Luh KT.
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [Abstract] [Full Text] [Related]

  • 5. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.
    Rolston KV, Vaziri I, Frisbee-Hume S, Streeter H, LeBlanc B.
    Chemotherapy; 2004 Nov; 50(5):214-20. PubMed ID: 15523180
    [Abstract] [Full Text] [Related]

  • 6. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
    Soussy CJ, Nguyen J, Goldstein F, Dabernat H, Andremont A, Leclercq R, Drugeon H, Cavallo P, Chardon H, Etienne J, Rio Y, Courvalin P.
    Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
    [Abstract] [Full Text] [Related]

  • 7. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
    Blondeau JM, Laskowski R, Bjarnason J, Stewart C.
    Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
    [Abstract] [Full Text] [Related]

  • 8. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
    Otani T, Tanaka M, Ito E, Kurosaka Y, Murakami Y, Onodera K, Akasaka T, Sato K.
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
    [Abstract] [Full Text] [Related]

  • 10. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
    Barry AL, Fuchs PC, Brown SD.
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of moxifloxacin against local bacterial isolates.
    Ling ML, Tan PL.
    Ann Acad Med Singap; 2001 Nov; 30(6):607-10. PubMed ID: 11817288
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R.
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [Abstract] [Full Text] [Related]

  • 13. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.
    Hoogkamp-Korstanje JA, Roelofs-Willemse J.
    J Antimicrob Chemother; 2000 Jan; 45(1):31-9. PubMed ID: 10629010
    [Abstract] [Full Text] [Related]

  • 14. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A, Thomson KS, Moland ES, Chartrand SA, Sanders CC.
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [Abstract] [Full Text] [Related]

  • 15. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV, Ho DH, LeBlanc B, Streeter H, Dvorak T.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [Abstract] [Full Text] [Related]

  • 16. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT, Counts C, Lody C, Carter O, Dodson S, Ojha N.
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [Abstract] [Full Text] [Related]

  • 17. In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
    Rolston KV, LeBlanc B, Ho DH, Bodey GP.
    J Antimicrob Chemother; 1990 Jul; 26(1):39-44. PubMed ID: 2211445
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV, Ho DH, LeBlanc B, Bodey GP.
    Chemotherapy; 1990 Jul; 36(5):365-72. PubMed ID: 2209169
    [Abstract] [Full Text] [Related]

  • 19. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison.
    Duggirala A, Joseph J, Sharma S, Nutheti R, Garg P, Das T.
    Indian J Ophthalmol; 2007 Jul; 55(1):15-9. PubMed ID: 17189881
    [Abstract] [Full Text] [Related]

  • 20. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
    Hidalgo M, Reyes J, Cárdenas AM, Díaz L, Rincón S, Vanegas N, Díaz PL, Castañeda E, Arias CA.
    Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.